Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9H611

UPID:
PIF1_HUMAN

ALTERNATIVE NAMES:
DNA repair and recombination helicase PIF1; PIF1/RRM3 DNA helicase-like protein

ALTERNATIVE UPACC:
Q9H611; B2RPL7; Q1W5B6; Q330H5; Q33E24

BACKGROUND:
The protein ATP-dependent DNA helicase PIF1, with alternative names DNA repair and recombination helicase PIF1 and PIF1/RRM3 DNA helicase-like protein, is essential for genome integrity. It efficiently unwinds G-quadruplex structures and RNA-DNA hybrids, crucial for preventing replication issues and double-strand breaks. Its role extends to telomeric DNA maintenance, where it inhibits telomerase activity, preventing excessive telomere elongation and ensuring genomic stability.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ATP-dependent DNA helicase PIF1 offers a pathway to identifying novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.